Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Drops By 49.1%

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 144,600 shares, a decline of 49.1% from the November 15th total of 284,000 shares. Currently, 3.6% of the shares of the stock are sold short. Based on an average daily volume of 2,000,000 shares, the short-interest ratio is presently 0.1 days.

Virax Biolabs Group Stock Down 6.1 %

Shares of VRAX opened at $1.70 on Thursday. The firm’s 50 day moving average is $1.94 and its 200-day moving average is $2.02. Virax Biolabs Group has a 12-month low of $0.60 and a 12-month high of $9.00.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.